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Editorial on the Research Topic
The Golden Future in Medicinal Chemistry: Perspectives and Resources From Old and New
Gold-Based Drug Candidates
Gold compounds started to play an important role in modern medicine after the discovery of the
efficacy of some gold salts against tuberculosis strains by Robert Koch (Sigel et al., 2018). In the
20’s of the last century, Jacques Forestier introduced the idea of using some gold(I) polymeric
thiolates for the cure of rheumatoid arthritis (RA), which lead to the birth of gold-based
treatments for RA (Kean et al., 1985). However, the turning point had been represented by the
development of the orally-administrable Au(I)-based drug auranofin (AF) by Sutton (Sutton,
1986).
Between the end of 1970s and the mid-1980s, the first scientific studies highlighted the in vitro
antiproliferative properties of auranofin against cancer cells (Mirabelli et al., 1985). This cornerstone
finding, also in the light of the heavy side effects of the platinum-based chemotherapy, triggered the
interest of the scientific community towards a possible “repurposing” of auranofin as prospective
anticancer drug.
In the following years, gold compounds have received large attention, and an impressive number
of structurally diverse gold(I) and gold(III) complexes were prepared, such as those stabilized by
phosphines or by nitrogen donors, that were found to induce important anticancer effects both
in vitro and in vivo (Marzo et al., 2019). Thanks to several mechanistic studies, preferential gold
binding to proteins, instead of DNA, was demonstrated with the occurrence of different pathways to
cytotoxicity. Mitochondria and oxidative phosphorylation’s pathways emerged as the primary
intracellular targets for cytotoxic gold complexes (Scalcon et al., 2018). Moreover, inhibition of
the seleno-enzyme thioredoxin reductase (TrxR) seems to be a common mechanistic trait to explain
the antiproliferative actions of several gold complexes, as strong TrxR inhibition may eventually lead
to apoptosis (Magherini et al., 2018).
Although the ferment that animates the scientific community on the investigation of gold-based
drug candidates, the real and entire picture of the involvedmechanisms andmodes of action for these
compounds remains largely undepicted.
To deepen the knowledge on the gold-based complexes, this Research Topic encloses some
fundamental contributions from worldwide outstanding researchers working in this field. In
particular, the areas covered range across the synthesis and characterization of new gold
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N-heterocyclic carbenes (Au-NHCs), to the study of protein
metalation processes, to the discovery of new mode-of-action,
and up to the search of unexplored molecular targets.
In the furrow of the research on the forefather of gold-based
compounds, namely auranofin, Tolbatov et al. described an
integrated experimental and theoretical study on the reactivity
of AF and its iodide derivative (AF-I) toward relevant amino acid
residues or their molecular models, such as the histidine, cysteine,
methionine, and selenocysteine, that may represent the possible
binding sites. Interestingly, the energetic barriers for the bond
formation between the gold compounds and the targets have been
calculated through computational methods. The obtained results
pointed out that the replacement of the thiosugar moiety with
iodide significantly affects the overall reactivity toward the
selected targets, contributing to enhance the antitumoral
activity of AF-I compared with AF.
A very informative analytical technique such as the high-
resolution ESI mass spectrometry, has been successfully applied
by Massai et al. to the study of protein metalation by a selected
panel of Au(III) complexes. These compounds were reacted with
two representative proteins, i.e. human serum albumin and
human carbonic anhydrase I, and with the C-terminal
dodecapeptide of TrxR. ESI-MS analysis permits to elucidate
the nature of the resulting metal–protein adducts from which the
main features of the occurring metallodrug–protein reactions can
be inferred. In some cases, MS data have been integrated with
other independent biophysical measurements for a
comprehensive description of the occurring processes.
Because of their oxidizing character, Au(III) complexes are
considered an interesting and promising class of potential
anticancer compounds involving, beyond the protein metalation,
probably also the oxidative cell stress. Radisavljević and co-workers
summarized in their review the chemistry of somemononuclear and
polynuclear gold(III) complexes. In particular, a special description
has been deserved for gold(III) complexes with nitrogen-donor inert
ligands and their kinetic behavior toward different biologically
relevant nucleophiles. Mechanisms of interaction with DNA,
serum albumin, and cytotoxic activity have been thoroughly
discussed also in the light of computational calculations.
To date, a great number of different structures of gold
compounds have been investigated for their anticancer
properties and, among these, Au-NHCs hold great potential. It
has been demonstrated that the antiproliferative effects of several
gold NHCs were related to their antimitochondrial effects
associated with potent inhibition of TrxR. Tong et al. in their
review have masterfully summarized the efforts spent in the last
years not only on the study of Au(III)-NHC, but also on porphyrin
and pincer-type cyclometalated gold complexes. From this
description, emerge the anticancer properties of gold(III)
compounds and the identification of molecular targets involved
in the mechanisms of action. Moreover, particular attention has
been devoted to the chemical formulation strategies that have been
adopted for the delivery of cytotoxic gold compounds, and for
ameliorating the in vivo toxicity.
Another class of drug candidates, i.e., imidazolate phosphane
gold(I) compounds, has been studied by Galassi and coworkers.
They performed enzymatic assays on the inhibition potential of
the studied compounds toward the dihydrofolate reductase
(DHFR), an enzyme involved in metabolic pathways crucial
for cancer cell’s growth and survival and overexpressed in
tumor cells. The results have been compared to those obtained
for TrxR, the most recognized molecular target for gold
compounds.
As completion of this Research Topic’s overview, the role of
gold compounds in anticancer immunity has been elucidated in a
review by Yue et al., that summarizes the complex relationship
between various gold derivatives and the immune system. Gold
complexes seem to reverse tumor immune escape and directly
facilitate the functions of immune cells, leading to enhanced
anticancer effects. In particular, the paper described the
antitumor effects of gold drugs and their relationships with
various aspects of antitumor immunity, including innate
immunity, adaptive immunity, immunogenic cell death, and
immune checkpoints, as well as their roles in adverse effects.
This Research Topic aims to give to the readership a new point
of view on the current research on gold-based drug candidates,
covering different aspects, from the synthesis of new molecules to
the study of their relationship with biomolecular targets and the
immune system. As Guest Editors, we believe that this collection
could be useful to disseminate the last advancements in the
research of gold anticancer drugs.
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